id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0150-0004,FDA,FDA-2007-D-0150,"Draft Guidance for Industry on Antibacterial Drug Products: Use of
Noninferiority Studies to Support Approval; Availability",Notice,NAD-Notice of Availability of Data,2007-10-15T04:00:00Z,2007,10,2007-10-12T04:00:00Z,2007-12-15T04:59:59Z,2019-10-17T19:08:57Z,,0,0,090000648042a3e3
FDA-2007-D-0150-0003,FDA,FDA-2007-D-0150,Guidance for Industry Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval,Other,GDL-Guidance,2007-10-15T04:00:00Z,2007,10,,,2019-10-17T19:20:59Z,,0,0,090000648042a3e2
FDA-2007-D-0150-0001,FDA,FDA-2007-D-0150,"Draft Guidance for Industry on Antibacterial Drug Products: Use of
Noninferiority Studies to Support Approval; Availability",Notice,NAD-Notice of Availability of Data,2007-10-15T04:00:00Z,2007,10,2007-10-12T04:00:00Z,2007-12-15T04:59:59Z,2019-10-17T19:07:33Z,,0,0,090000648042a3df
FDA-2007-D-0150-0002,FDA,FDA-2007-D-0150,Guidance,Supporting & Related Material,GDL-Guidance,2007-10-15T04:00:00Z,2007,10,,,2008-04-04T00:34:10Z,,0,0,090000648042a3e1